Search Result

Results for "

glucose transporter inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GLUT (30) SGLT (8) Acetyl-CoA Carboxylase (2) Akt (5) Amylases (2) Apoptosis (6) Autophagy (1) Biochemical Assay Reagents (1) Caspase (1) Dipeptidyl Peptidase (2) Disulfidptosis (3) DNA/RNA Synthesis (3) Drug Derivative (1) Endogenous Metabolite (3) FXR (2) GLP Receptor (2) HCV (4) Influenza Virus (1) Lactate Dehydrogenase (1) Mitochondrial Metabolism (1) mTOR (1) NF-κB (2) NKCC (1) P-glycoprotein (2) Parasite (1) Phosphatase (1) Reactive Oxygen Species (ROS) (1) Reference Standards (7) Sirtuin (2) Sodium Channel (1) TNF Receptor (2) Topoisomerase (2) URAT1 (1)
By Research Areas:	Cancer (24) Cardiovascular Disease (2) Endocrinology (1) Infection (6) Inflammation/Immunology (7) Metabolic Disease (23) Neurological Disease (3)

By Targets:

GLUT (30)

SGLT (8)

Acetyl-CoA Carboxylase (2)

Akt (5)

Amylases (2)

Apoptosis (6)

Autophagy (1)

Biochemical Assay Reagents (1)

Caspase (1)

Dipeptidyl Peptidase (2)

Disulfidptosis (3)

DNA/RNA Synthesis (3)

Drug Derivative (1)

Endogenous Metabolite (3)

FXR (2)

GLP Receptor (2)

HCV (4)

Influenza Virus (1)

Lactate Dehydrogenase (1)

Mitochondrial Metabolism (1)

mTOR (1)

NF-κB (2)

NKCC (1)

P-glycoprotein (2)

Parasite (1)

Phosphatase (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (7)

Sirtuin (2)

Sodium Channel (1)

TNF Receptor (2)

Topoisomerase (2)

URAT1 (1)

By Research Areas:

Cancer (24)

Cardiovascular Disease (2)

Endocrinology (1)

Infection (6)

Inflammation/Immunology (7)

Metabolic Disease (23)

Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Targets Recommended: GLUT Glucose-6-Phosphate Isomerase (GPI) SGLT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100017

BAY-876 Maximum Cited Publications 52 Publications Verification	GLUT Disulfidptosis	Cancer
BAY-876, a chemical probe, is an orally active and selective glucose transporter 1 (GLUT1) inhibitor with an IC₅₀ of 2 nM. BAY-876 is >130-fold more selective for GLUT1 than GLUT2, GLUT3, and GLUT4. BAY-876 is also a potent blocker of glycolytic metabolism and ovarian cancer growth. In addition, BAY-876 can induce the formation of disulfide bonds in actin cytoskeletal proteins, leading to the occurrence of cellular disulfidptosis .

HY-123986

CTPI-2 10+ Cited Publications	Mitochondrial Metabolism	Inflammation/Immunology Cancer
CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a K_D of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. Antitumor activity .

HY-145597

KL-11743 5 Publications Verification	GLUT Disulfidptosis	Metabolic Disease Cancer
KL-11743 is a potent, orally active, and glucose-competitive inhibitor of the class I glucose transporters, with IC₅₀s of 115, 137, 90, and 68 nM for GLUT1, GLUT2, GLUT3, and GLUT4, respectively. KL-11743 specifically blocks glucose metabolism. KL-11743 can synergize with electron transport inhibitors to induce cell death. In addition, KL-11743 can induce the formation of disulfide bonds in actin cytoskeletal proteins, leading to the occurrence of cellular disulfidptosis .

HY-19331

WZB117 20+ Cited Publications	GLUT	Cancer
WZB117 is a glucose transporter 1 (Glut1) inhibitor, which downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo.

HY-N0668

Rubusoside 2 Publications Verification	GLUT Amylases NF-κB	Metabolic Disease Inflammation/Immunology Cancer
Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) .

HY-18728

STF-31 15+ Cited Publications	GLUT Autophagy	Cancer
STF-31 is a selective inhibitor of glucose transporter 1 (GLUT1), with an IC₅₀ of 1 μM. STF-31 is also a NAMPT inhibitor. STF-31 inhibits glucose uptake in renal cell carcinoma (RCC) 4 cells .

HY-123011

Henagliflozin SHR3824	SGLT	Metabolic Disease
Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC₅₀ values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research .

HY-A0080

Aminohippurate sodium 4 Publications Verification Sodium p-aminohippurate; p-Aminohippuric acid sodium salt	Biochemical Assay Reagents
Aminohippurate sodium is a renal tubular transport inhibitor and a substrate for organic anion transporters. Aminohippurate sodium inhibits renal tubular reabsorption of phosphate and promotes increased urinary phosphate excretion. Aminohippurate sodium inhibits renal tubular reabsorption of vitamin C as well as the transport of glucose .

HY-N0468

Rebaudioside D 1 Publications Verification	FXR Acetyl-CoA Carboxylase	Metabolic Disease
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-139605

GLUT inhibitor-1 1 Publications Verification	GLUT	Inflammation/Immunology Cancer
GLUT inhibitor-1 is a potent and orally active inhibitor of glucose transporters, targeting both GLUT1 and GLUT3, with IC₅₀s of 242 nM and 179 nM, respectively. GLUT inhibitor-1 has the potential for the reaesrch of cancers and autoimmune diseases .

HY-101849

Fasentin 4 Publications Verification	GLUT TNF Receptor Apoptosis	Cardiovascular Disease Cancer
Fasentin, a potent glucose uptake inhibitor, inhibits GLUT-1/GLUT-4 transporters. Fasentin preferentially inhibits GLUT4 (IC₅₀=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death. Fasentin is also a tumor necrosis factor (TNF) apoptosis-inducing ligand sensitizer. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity .

HY-124113

4'-Bromo-resveratrol 4′‐BR	Sirtuin Apoptosis Caspase Lactate Dehydrogenase GLUT	Metabolic Disease Inflammation/Immunology Cancer
4'-Bromo-resveratrol (4′‐BR) is a dual SIRT1/SIRT3 inhibitor with an IC₅₀ of 0.2 mM for both targets. 4'-Bromo-resveratrol induces caspase-dependent apoptosis, induces G0/G1 cell cycle arrest, and inhiibits proliferation. 4'-Bromo-resveratrol reduces lactate production, glucose uptake, and NAD ⁺/NADH ratio, and downregulates lactate dehydrogenase A and glucose transporter 1 (GLUT1). 4'-Bromo-resveratrol can be used for the research of melanoma .

HY-120103

PF-06649298 1 Publications Verification	Sodium Channel	Metabolic Disease
PF-06649298 is a *sodium-coupled citrate transporter* (NaCT or SLC13A5)** inhibitor. PF-06649298 specifically interacts with NaCT with an IC₅₀ value of 16.2 μM to inhibits the transport of citrate in human hepatocytes. PF-06649298 can be used for the research of regulating glucose metabolism and lipid metabolism .

HY-128723

Dapagliflozin impurity	SGLT	Others
Dapagliflozin impurity is an enantiomer of Dapagliflozin which is a sodium-glucose transporter 2 inhibitor .

HY-N7433

4,6-O-Ethylidene-α-D-glucose Ethylidene-glucose	GLUT Endogenous Metabolite	Metabolic Disease
4,6-O-ethylidene-α-D-glucose (Ethylidene-glucose), a glucose derivative, is a competitive exofacial binding-site inhibitor on glucose transporter 1 (GLUT1) with a K_i of 12 mM for wild-type 2-deoxy-D-glucose transport .

HY-N6935

Sennidin B	DNA/RNA Synthesis HCV Akt GLUT	Infection Metabolic Disease
Sennidin B, a stereoisomer isolated from the leaves of Cassia angustifolia, has lower activity than Sennidin A. Sennidin A inhibits HCV NS3 helicase, with an IC₅₀ of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation .

HY-161501

3-Fluoro-evodiamine glucose	GLUT Topoisomerase Apoptosis	Cancer
3-Fluoro-evodiamine glucose (Compound 8) is an evodiamine-glucose conjugate. 3-Fluoro-evodiamine glucose activates the expression of glucose transporter 1 (GLUT1), and inhibits topoisomerase I/II. 3-Fluoro-evodiamine glucose induces apoptosis and arrests the cell cycle at G2/M phase. 3-Fluoro-evodiamine glucose exhibits antitumor efficacy in vivo and in vitro, without significant toxicity .

HY-B1080A

Tilorone 2 Publications Verification	Influenza Virus Akt	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Tilorone is an orally active antiviral agent and interferon inducer that also has potential antineoplastic, immunomodulatory, and metabolic modulating effects. Tilorone induces an abnormally delayed interferon response and primarily stimulates interferon production in lymphoid tissue. Thus, Tilorone exerts antiviral effects and can be used as a chemotherapeutic agent. Tilorone has the potential to inhibit type 2 diabetes by increasing glucose uptake in vivo and in skeletal muscle cells by enhancing Akt2/AS160 signaling and glucose transporter levels .

HY-151486

GLUT1-IN-1	GLUT	Cancer
GLUT1-IN-1 is a glucose transporter 1 (GLUT1) inhibitor and has a GLUT1-specific inactivation ability. GLUT1-IN-1 exhibits concentration-dependent cytotoxicity for HeLa, A549 and HepG2 cells with IC₅₀ values of 5.49 μM, 11.14 μM, and 8.73 μM, respectively. GLUT1-IN-1 can be used for the research of photodynamic therapy (PDT) and severals cancer .

HY-10449A

Luseogliflozin hydrate TS 071 hydrate	SGLT	Metabolic Disease
Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC₅₀ of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM) .

HY-153113

Rongliflozin DJT1116PG	SGLT	Endocrinology
Rongliflozin (DJT1116PG) is a selective and orally active inhibitor of sodium-glucose co-transporter-2 (SGLT-2). Rongliflozin can be used for the research of type 2 diabetes mellitus (T2DM) .

HY-139047

SW157765	GLUT	Cancer
SW157765 is a selective non-canonical glucose transporter GLUT8 (SLC2A8) inhibitor. KRAS/KEAP1 double mutant NSCLC cells are selectively sensitive to the SW157765, due to the convergent consequences of dual KRAS and NRF2 modulation of metabolic and xenobiotic gene regulatory programs .

HY-16605

SIRT6-IN-6	Sirtuin GLUT	Metabolic Disease
SIRT6-IN-6 (compound 6d) is a potent and selective SIRT6 inhibitor with an IC₅₀ of 4.93 μM and a K_i of ~10 μM. SIRT6-IN-6 shows selectivity against other members of the HDAC family (SIRT1-3 and HDAC1-11). SIRT6-IN-6 significantly increases the level of glucose transporter GLUT-1, thereby reducing blood glucose in a mouse model of type 2 diabetes. SIRT6-IN-6 can be used for type 2 diabetes research .

HY-153612

MMV009085	GLUT Parasite	Infection Inflammation/Immunology
MMV009085 is a potent PfHT1 (Plasmodium falciparum hexose transporter)-specific inhibitor and a potential anti-malarial agent . MMV009085 is also a human glucose transporter inhibitor, it has high potency in inhibiting both glucose uptake (IC₅₀: 2.6 μM in glucose uptake assay) and growth of the parasites (EC₅₀: 1.23±0.04 μM against 3D7) .

HY-N6936

Sennidin A	DNA/RNA Synthesis HCV Akt GLUT	Infection
Sennidin A, isolated from the leaves of Cassia angustifolia, inhibits HCV NS3 helicase, with an IC₅₀ of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation .

HY-176050

Rapaglutin A RgA; JW11-D2	GLUT	Cancer
Rapaglutin A is a glucose transporter (GLUT) inhibitor. Rapaglutin A is a pan-GLUT inhibitor of Class I isoforms GLUT1, GLUT3, and GLUT4 with an IC₅₀ of 12 nM. Rapaglutin A has an inhibitory effect on A549 proliferation .

HY-158056

URAT1/GLUT9-IN-1	GLUT URAT1	Metabolic Disease
URAT1/GLUT9-IN-1 (compound 29) can inhibit both uric acid transporter 1 (URAT1) (IC₅₀=2.01 μM) and glucose transporter 9 (GLUT9) (IC₅₀=18.21 μM). URAT1/GLUT9-IN-1 exhibits favorable pharmacokinetic properties and oral bioavailability. URAT1/GLUT9-IN-1 can be uesd for gout and hyperuricemia research .

HY-115606

ML077	NKCC Endogenous Metabolite	Neurological Disease
ML007 is a selective antagonist targeting the neuron-specific potassium-chloride co-transporter 2 (KCC2) with an IC₅₀ for KCC2 is 537 nM, while its inhibitory activity on KCC1 is extremely weak (IC₅₀ > 50 μM). ML077 inhibits the chloride ion excretion function of KCC2, increasing the intracellular chloride ion concentration, thereby enhancing the depolarization mediated by chloride ion channels. ML007 can promote glucose-stimulated insulin secretion (GSIS) without relying on KATP channels. ML007 can be used to study the functions related to pain, epilepsy, and insulin secretion .

HY-N0668R

Rubusoside (Standard)	GLUT Amylases NF-κB Reference Standards	Metabolic Disease Inflammation/Immunology Cancer
Rubusoside (Standard) is the analytical standard of Rubusoside. This product is intended for research and analytical applications. Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) .

HY-N0468R

Rebaudioside D (Standard)	Reference Standards Acetyl-CoA Carboxylase FXR	Metabolic Disease
Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-168989

Olorigliflozin	SGLT	Metabolic Disease
Olorigliflozin is a sodium glucose co-transporter inhibitor with anti-hyperglycemic effects .

HY-N7433R

4,6-O-Ethylidene-α-D-glucose (Standard) Ethylidene-glucose (Standard)	Reference Standards GLUT Endogenous Metabolite	Metabolic Disease
4,6-O-ethylidene-α-D-glucose (Ethylidene-glucose), a glucose derivative, is a competitive exofacial binding-site inhibitor on glucose transporter 1 (GLUT1) with a Ki of 12 mM for wild-type 2-deoxy-D-glucose transport .

HY-112807

SGLT inhibitor-1	SGLT	Metabolic Disease
SGLT inhibitor-1 is a potent dual inhibitor of *sodium glucose* co-transporter proteins (SGLTs)*, inhibits* hSGLT1 and hSGLT2 with IC₅₀s of 43 nM and 9 nM, respectively .

HY-178167

SGLT2-IN-3	SGLT	Metabolic Disease
SGLT2-IN-3 is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. SGLT2-IN-3 can inhibit glucose uptake. SGLT2-IN-3 can be used for the research of metabolic disease, such as diabetes .

HY-165438

Sergliflozin-A	SGLT	Others
Sergliflozin-A is a compound used to inhibit type 2 diabetes. It can inhibit glucose transporters in the kidney, competitively inhibit hSGLT1 and hSGLT2, and mutations at different sites have different effects on its inhibitory effect.

HY-N6936R

Sennidin A (Standard)	Reference Standards HCV Akt GLUT	Infection
Sennidin A (Standard) is the analytical standard of Sennidin A. This product is intended for research and analytical applications. Sennidin A, isolated from the leaves of Cassia angustifolia, inhibits HCV NS3 helicase, with an IC50 of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation .

HY-162132

WZB117-PPG	GLUT	Cancer
WZB117-PPG is a glucose transporter 1 (GLUT1) inhibitor with anticancer activity. WZB117-PPG has remarkable photolysis efficiency and cytotoxicity to cancer cells under visible light irradiation .

HY-16442

S-3483	Phosphatase	Metabolic Disease
S-3483, a Chlorogenic acid (HY-N0055) derivative, is a reversible, linear competitive glucose-6-phosphatase (Glc-6-Pase) system inhibitor. S-3483 inhibits Glc-6-Pase with a K_i 129 nM in rat liver microsomes. S-3483 specifically inhibits Glc-6-P transporter of renal and liver microsomes .

HY-155034

Antitumor agent-102	Topoisomerase GLUT	Cancer
Antitumor agent-102 (compound 10) is a conjugate of Topoisomerase I inhibitor SN38 and glucose transporter inhibitor, targeting to colorectal cancer. Antitumor agent-102 induces higher concentrations of free SN38 in tumor tissues than Irinotecan (HY-16562) .

HY-N6935R

Sennidin B (Standard)	Reference Standards HCV Akt GLUT	Infection Metabolic Disease
Sennidin B (Standard) is the analytical standard of Sennidin B. This product is intended for research and analytical applications. Sennidin B, a stereoisomer isolated from the leaves of Cassia angustifolia, has lower activity than Sennidin A. Sennidin A inhibits HCV NS3 helicase, with an IC50 of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation .

HY-170313

GLUT-1-IN-4	GLUT Apoptosis Reactive Oxygen Species (ROS)	Cancer
GLUT-1-IN-4 (Compound 13) is the p53 protein-dependent inhibitor for GLUT-1 glucose transporter. GLUT-1-IN-4 inhibits the proliferation of multiple cancer cells with IC₅₀ in submicromolar levels. GLUT-1-IN-4 arrests the cell cycle, stimulates oxidative stress, and induces apoptosis .

HY-101849R

Fasentin (Standard)	Reference Standards GLUT TNF Receptor Apoptosis	Cardiovascular Disease Cancer
Fasentin (Standard) is the analytical standard of Fasentin. This product is intended for research and analytical applications. Fasentin, a potent glucose uptake inhibitor, inhibits GLUT-1/GLUT-4 transporters. Fasentin preferentially inhibits GLUT4 (IC50=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death. Fasentin is also a tumor necrosis factor (TNF) apoptosis-inducing ligand sensitizer. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity .

HY-176051

Rapaglutin E RgE	GLUT	Cancer
Rapaglutin E (RgE) is a glucose transporter (GLUT) inhibitor. Rapaglutin E exhibits dose-dependent inhibition of [ ³H]-2DG uptake in A549, Jurkat T, PANC10.05, and RBC, with IC₅₀ values 8.9 nM, 3.1 nM, 35.5 nM, 74.2 nM. Rapaglutin E inhibits cell proliferation in A549, PANC10.05, HeLa, Jurkat T, and HEK293T cells .

HY-10289

Carmegliptin RO-4876904	Dipeptidyl Peptidase GLP Receptor P-glycoprotein	Metabolic Disease
Carmegliptin (RO-4876904) is an orally active and potent DPP IV inhibitor with a human DPP IV IC₅₀ of 6.8 nM. Carmegliptin binds to the S1 pocket of DPP IV, blocks the degradation of GLP 1, potentiates endogenous GLP 1, increases plasma insulin levels, alleviates hyperglycemia, improves glucose tolerance. Carmegliptin acts as a substrate for human P glycoprotein without inhibiting the transporter, shows low in vitro cell permeability. Carmegliptin can be used for the research of type 2 diabetes, non insulin dependent diabetes mellitus .

HY-138976

NV-5440	mTOR GLUT	Neurological Disease Metabolic Disease Cancer
NV-5440 (Compound I-120) is an mTORC1 inhibitor and **glucose transporter** inhibitor. NV-5440 targets GLUT-1, -2, -3, and -4, and shows no activity against GLUT-5. NV-5440 inhibits glucose uptake .

HY-177903

Triptolide-6-succinate-β-D-glucose	Drug Derivative GLUT DNA/RNA Synthesis	Cancer
Triptolide-6-succinate-β-D-glucose (Compound 2) is a glucose-conjugated derivative of Triptolide (HY-32735). Triptolide-6-succinate-β-D-glucose is a tumor-selective prodrug targeting **glucose transporters ( GLUT*). Triptolide-6-succinate-β-D-glucose* can induce the degradation of the RPB subunit of RNA polymerase II. Triptolide-6-succinate-β-D-glucose inhibits the proliferation of HEK293T cells with an IC₅₀ value of 268 nM. Triptolide-6-succinate-β-D-glucose can be used for the research of cancer, such as prostatic cancer .

HY-10289A

Carmegliptin hydrochloride RO-4876904 hydrochloride	Dipeptidyl Peptidase GLP Receptor P-glycoprotein	Metabolic Disease
Carmegliptin hydrochloride (RO-4876904 hydrochloride) is an orally active and potent DPP‑IV inhibitor with a human DPP‑IV IC₅₀ of 6.8 nM. Carmegliptin hydrochloride binds to the S1 pocket of DPP‑IV, blocks the degradation of GLP‑1, potentiates endogenous GLP‑1, increases plasma insulin levels, alleviates hyperglycemia, improves glucose tolerance. Carmegliptin hydrochloride acts as a substrate for human P‑glycoprotein without inhibiting the transporter, shows low in vitro cell permeability. Carmegliptin hydrochloride can be used for the research of type 2 diabetes, non‑insulin‑dependent diabetes mellitus .

HY-179631

2DG-ODDA	Apoptosis	Cancer
2DG-ODDA is a 2-deoxyglucose (2-DG) (HY-13966) derivative with potent antitumor activity. 2DG-ODDA induces apoptosis, and reduces ATP production. 2DG-ODDA is taken up through both fatty acid and glucose transporters and is cleaved by α-Mannosidase (HY-P2950), releases 2DG to inhibit N-glycosylation and disrupt cellular metabolism. 2DG-ODDA inhibits tumor growth in a 4T1 mouse model. 2DG-ODDA can be used for the research of triple-negative breast cancer (TNBC) .

HY-100017R

BAY-876 (Standard)	Reference Standards GLUT Disulfidptosis	Cancer
BAY-876 (Standard) is the analytical standard of BAY-876 (HY-100017). This product is intended for research and analytical applications. BAY-876, a chemical probe, is an orally active and selective glucose transporter 1 (GLUT1) inhibitor with an IC50 of 2 nM. BAY-876 is >130-fold more selective for GLUT1 than GLUT2, GLUT3, and GLUT4. BAY-876 is also a potent blocker of glycolytic metabolism and ovarian cancer growth. In addition, BAY-876 can induce the formation of disulfide bonds in actin cytoskeletal proteins, leading to the occurrence of cellular disulfidptosis .

Cat. No.	Product Name

HY-L064

Glutamine Metabolism Compound Library

1,690 compounds

Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH.

Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment.

MCE owns a unique collection of 1,690 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

HY-L083

Anti-Cancer Metabolism Compound Library

3,552 compounds

Mutations in oncogenes and tumor suppressor genes can modify multiple signaling pathways and in turn cell metabolism, which facilitates tumorigenesis. The paramount hallmark of tumor metabolism is “aerobic glycolysis” or the Warburg effect, coined by Otto Warburg in 1926, in which cancer cells produce most of energy from glycolysis pathway regardless of whether in aerobic or anaerobic condition. Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside. The increased uptake of glucose is facilitated by the overexpression of several isoforms of membrane glucose transporters (GLUTs). Likewise, the metabolic pathways of glutamine, amino acid and fat metabolism are also altered. Recent trends in anti-cancer drug discovery suggests that targeting the altered metabolic pathways of cancer cells result in energy crisis inside the cancer cells and can selectively inhibit cancer cell proliferation by delaying or suppressing tumor growth.

MCE provides a unique collection of 3,552 compounds which cover various tumor metabolism-related signaling pathways. These compounds can be used for anti-cancer metabolism targets identification, validation as well anti-cancer drug discovery.

Cat. No.	Product Name	Category	Target	Chemical Structure